Company: RGBP
Filing Date: 2025-02-24
Form Type: 253G1
Source: 0001493152-25-008067
Chunk: 46

Company: Regen BioPharma Inc
Filing Date: 2025-02-24
Form: 253G1
Chunk 46
---
320 square feet of office space at 4700 Spring Street, Suite 304, La Mesa, California 91942. The property is utilized as office space. We believe that the foregoing properties are adequate to meet our current needs for office space.

On January 13, 2022 Regen Biopharma, Inc. entered into a sublease agreement with BST Partners (“BST”) whereby Regen Biopharma, Inc. would sublet the aforementioned office space located at 4700 Spring Street, Suite 304, La Mesa, California 91942 from BST on a month to month basis for $5,000 per month beginning January 14, 2022. BST Partners is controlled by David Koos who serves as the sole officer and director of Regen Biopharma, Inc.

On April 26, 2024 the Company and BST Partners ( Sublessor) agreed to amend that sublease agreement (“Sublease Agreement”) entered into between the parties as follows:

The Company agreed that in addition to the base rent of $5,000 per month to be paid by the Company to Sublessor the Company shall also reimburse Sublessor for any and all shared expenses as such term is defined within the Sublease Agreement.

LEGAL PROCEEDINGS .

None

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

As of September 30, 2023 we had Cash of $ 121,037 and as of September 30, 2024 we had cash of $716. The decrease in cash of approximately 99% is primarily attributable to cash expensed in the operation of the Company’s business.:

As of September 30, 2023 we had Accounts Receivable, Related Party of $0 and as of September 30, 2024 we had Accounts Receivable, Related Party of $ 94,873. The increase in Accounts Receivable, Related Party is attributable to the accrual by Zander Therapeutics, Inc. of licensing fees due and payable to the Company.

As of September 30, 2023 we had Prepaid Expenses of $0 and as of September 30, 2024 we had prepaid expenses of $59,289 attributable to an overpayment of $200 paid to a patent attorney , the payment of 20,068 shares of the Company’s Series A Preferred stock paid to an independent consultant for services to be provided for a period of one year commencing on April 26, 2024 and